Leveraging University of Glasgow and University of Southern Denmark research, Caldan is targeting a free fatty acid receptor associated with fatty liver disease and type 2 diabetes.
Caldan Therapeutics, a UK-based metabolic disease therapy developer exploiting research from University of Glasgow and University of Southern Denmark, secured £2m ($2.4m) on Tuesday in a round led by research charity LifeArc.
LifeArc invested $1.8m to lead the round, which was also backed by venture capital firm Epidarex Capital.
Founded in 2015, Caldan is developing drugs intended to activate free fatty acid receptors associated with non-alcoholic steatohepatitis (Nash), where fat accumulates in the liver and potentially causes scarring.
